Free Trial

TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

-1.98 (-20.75%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
353,134 shs
Average Volume
31,527 shs
Market Capitalization
$205.33 million
P/E Ratio
Dividend Yield
Price Target

TriSalus Life Sciences MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
111.6% Upside
$16.00 Price Target
Short Interest
7.13% of Float Sold Short
Dividend Strength
News Sentiment
0.93mentions of TriSalus Life Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.36 out of 5 stars

Medical Sector

294th out of 923 stocks

Surgical & Medical Instruments Industry

43rd out of 98 stocks

TLSI stock logo

About TriSalus Life Sciences Stock (NASDAQ:TLSI)

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

TLSI Stock Price History

TLSI Stock News Headlines

TLSI TriSalus Life Sciences, Inc.
TriSalus Life Sciences Inc
TriSalus Life Sciences, Inc. Q4 sales increase
TriSalus Life Sciences Inc TLSI
Maxim Group Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI)
See More Headlines
Receive TLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Previous Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$18.51 million
Book Value
($1.29) per share


Free Float
Market Cap
$205.33 million
Not Optionable
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Ms. Mary T. Szela B.S.N. (Age 60)
    M.B.A., CEO, President & Director
    Comp: $880.67k
  • Mr. Sean Edward Murphy (Age 71)
    CFO & Director
    Comp: $628.75k
  • Dr. Steven C. Katz F.A.C.S. (Age 49)
    M.D., Chief Medical Officer & Chairman of Scientific Advisory Board
    Comp: $849.89k
  • Ms. Lori Ann Santamaria
    Vice President of Operations
  • Dr. Bryan F. Cox Ph.D. (Age 62)
    Chief Scientific & Manufacturing Officer
  • Mr. James E. Young
    Senior VP of Investor Relations & Treasurer
  • Ms. Rachel Garcia
    Marketing Manager
  • Dr. Richard B. Marshak M.B.A. (Age 65)
    MBA, VMD, Senior Vice President of Corporate Development & Strategy
  • Ms. Jennifer L. Stevens J.D. (Age 63)
    Chief Regulatory Officer
    Comp: $630k
  • Ms. Jodi Devlin (Age 62)
    President of Commercial Operations

TLSI Stock Analysis - Frequently Asked Questions

Should I buy or sell TriSalus Life Sciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TriSalus Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TLSI shares.
View TLSI analyst ratings
or view top-rated stocks.

What is TriSalus Life Sciences' stock price target for 2024?

1 Wall Street research analysts have issued 1-year target prices for TriSalus Life Sciences' shares. Their TLSI share price targets range from $16.00 to $16.00. On average, they predict the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 111.6% from the stock's current price.
View analysts price targets for TLSI
or view top-rated stocks among Wall Street analysts.

How have TLSI shares performed in 2024?

TriSalus Life Sciences' stock was trading at $8.45 at the beginning of the year. Since then, TLSI shares have decreased by 10.5% and is now trading at $7.56.
View the best growth stocks for 2024 here

When is TriSalus Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024.
View our TLSI earnings forecast

How were TriSalus Life Sciences' earnings last quarter?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) released its quarterly earnings data on Monday, April, 1st. The company reported ($1.56) EPS for the quarter. The business earned $5.72 million during the quarter.

What guidance has TriSalus Life Sciences issued on next quarter's earnings?

TriSalus Life Sciences issued an update on its FY 2024 earnings guidance on Thursday, May, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $27.8 million-.

Who are TriSalus Life Sciences' major shareholders?

TriSalus Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Connecticut Wealth Management LLC (0.17%), Anson Capital Inc. (0.09%) and Tyche Wealth Partners LLC (0.04%).

How do I buy shares of TriSalus Life Sciences?

Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TLSI) was last updated on 5/26/2024 by Staff

From Our Partners